Industry & Policy News

[University of Alberta] A renowned expert is joining the University of Alberta to research a critical underlying defect in all types of diabetes, with the goal of improving treatment, thanks to support through the Canada Excellence Research Chairs program.

[STAT News] Academia is in the midst of an unprecedented exodus of life science researchers, many of whom are leaving for lucrative jobs in the private sector.

[NHMRC] Professor Gail Risbridger and her research team from Monash University will receive $5 million in funding over 5 years for research to advance immunotherapy treatments for treating prostate cancer.

[Nature] In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The approval by the Medicines and Healthcare products Regulatory Agency (MHRA) follows promising results from clinical trials that tested a one-time treatment, which is administered by intravenous infusion.

[UMass Chan Medical School] “What we will do with this American Cancer Society grant is try to understand why sometimes senescence is good and stops tumors from growing and other times it’s bad and leads to immune suppression,” Dr. Ruscetti said.

[McKesson Corporation] Biologics by McKesson has announced the US FDA approval of FRUZAQLA, an oral targeted therapy for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.